Cargando…

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma

Esophageal adenocarcinoma (EAC) is a disease with dismal treatment outcomes. Response to neoadjuvant chemoradiation (CRT) varies greatly. Although the underlying mechanisms of CRT resistance are not identified, accumulating evidence indicates an important role for local antitumor immunity. To explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Goedegebuure, R.S.A., Harrasser, M., de Klerk, L.K., van Schooten, T.S., van Grieken, N.C.T., Eken, M., Grifhorst, M.S., Pocorni, N., Jordanova, E.S., van Berge Henegouwen, M.I., Pouw, R.E., Verheul, H.M.W., van der Vliet, J.J., van Laarhoven, H.W.M., Thijssen, V.L.J.L, Bass, A.J., De Gruijl, T.D., Derks, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344794/
https://www.ncbi.nlm.nih.gov/pubmed/34377591
http://dx.doi.org/10.1080/2162402X.2021.1954807
_version_ 1783734503290699776
author Goedegebuure, R.S.A.
Harrasser, M.
de Klerk, L.K.
van Schooten, T.S.
van Grieken, N.C.T.
Eken, M.
Grifhorst, M.S.
Pocorni, N.
Jordanova, E.S.
van Berge Henegouwen, M.I.
Pouw, R.E.
Verheul, H.M.W.
van der Vliet, J.J.
van Laarhoven, H.W.M.
Thijssen, V.L.J.L
Bass, A.J.
De Gruijl, T.D.
Derks, S.
author_facet Goedegebuure, R.S.A.
Harrasser, M.
de Klerk, L.K.
van Schooten, T.S.
van Grieken, N.C.T.
Eken, M.
Grifhorst, M.S.
Pocorni, N.
Jordanova, E.S.
van Berge Henegouwen, M.I.
Pouw, R.E.
Verheul, H.M.W.
van der Vliet, J.J.
van Laarhoven, H.W.M.
Thijssen, V.L.J.L
Bass, A.J.
De Gruijl, T.D.
Derks, S.
author_sort Goedegebuure, R.S.A.
collection PubMed
description Esophageal adenocarcinoma (EAC) is a disease with dismal treatment outcomes. Response to neoadjuvant chemoradiation (CRT) varies greatly. Although the underlying mechanisms of CRT resistance are not identified, accumulating evidence indicates an important role for local antitumor immunity. To explore the immune microenvironment in relation to response to CRT we performed an in-depth analysis using multiplex immunohistochemistry, flow cytometry and mRNA expression analysis (NanoString) to generate a detailed map of the immunological landscape of pretreatment biopsies as well as peripheral blood mononuclear cells (PBMCs) of EAC patients. Response to CRT was assessed by Mandard’s tumor regression grade (TRG), disease-free- and overall survival. Tumors with a complete pathological response (TRG 1) to neoadjuvant CRT had significantly higher tumor-infiltrating T cell levels compared to all other response groups (TRG 2–5). These T cells were also in closer proximity to tumor cells in complete responders compared to other response groups. Notably, immune profiles of near-complete responders (TRG 2) showed more resemblance to non-responders (TRG 3–5) than to complete responders. A high CD8:CD163 ratio in the tumor was associated with an improved disease-free survival. Gene expression analyses revealed that T cells in non-responders were Th2-skewed, while complete responders were enriched in cytotoxic immune cells. Finally, complete responders were enriched in circulating memory T cells. preexisting immune activation enhances the chance for a complete pathological response to neoadjuvant CRT. This information can potentially be used for future patient selection, but also fuels the development of immunomodulatory strategies to enhance CRT efficacy.
format Online
Article
Text
id pubmed-8344794
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-83447942021-08-09 Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma Goedegebuure, R.S.A. Harrasser, M. de Klerk, L.K. van Schooten, T.S. van Grieken, N.C.T. Eken, M. Grifhorst, M.S. Pocorni, N. Jordanova, E.S. van Berge Henegouwen, M.I. Pouw, R.E. Verheul, H.M.W. van der Vliet, J.J. van Laarhoven, H.W.M. Thijssen, V.L.J.L Bass, A.J. De Gruijl, T.D. Derks, S. Oncoimmunology Original Research Esophageal adenocarcinoma (EAC) is a disease with dismal treatment outcomes. Response to neoadjuvant chemoradiation (CRT) varies greatly. Although the underlying mechanisms of CRT resistance are not identified, accumulating evidence indicates an important role for local antitumor immunity. To explore the immune microenvironment in relation to response to CRT we performed an in-depth analysis using multiplex immunohistochemistry, flow cytometry and mRNA expression analysis (NanoString) to generate a detailed map of the immunological landscape of pretreatment biopsies as well as peripheral blood mononuclear cells (PBMCs) of EAC patients. Response to CRT was assessed by Mandard’s tumor regression grade (TRG), disease-free- and overall survival. Tumors with a complete pathological response (TRG 1) to neoadjuvant CRT had significantly higher tumor-infiltrating T cell levels compared to all other response groups (TRG 2–5). These T cells were also in closer proximity to tumor cells in complete responders compared to other response groups. Notably, immune profiles of near-complete responders (TRG 2) showed more resemblance to non-responders (TRG 3–5) than to complete responders. A high CD8:CD163 ratio in the tumor was associated with an improved disease-free survival. Gene expression analyses revealed that T cells in non-responders were Th2-skewed, while complete responders were enriched in cytotoxic immune cells. Finally, complete responders were enriched in circulating memory T cells. preexisting immune activation enhances the chance for a complete pathological response to neoadjuvant CRT. This information can potentially be used for future patient selection, but also fuels the development of immunomodulatory strategies to enhance CRT efficacy. Taylor & Francis 2021-08-04 /pmc/articles/PMC8344794/ /pubmed/34377591 http://dx.doi.org/10.1080/2162402X.2021.1954807 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Goedegebuure, R.S.A.
Harrasser, M.
de Klerk, L.K.
van Schooten, T.S.
van Grieken, N.C.T.
Eken, M.
Grifhorst, M.S.
Pocorni, N.
Jordanova, E.S.
van Berge Henegouwen, M.I.
Pouw, R.E.
Verheul, H.M.W.
van der Vliet, J.J.
van Laarhoven, H.W.M.
Thijssen, V.L.J.L
Bass, A.J.
De Gruijl, T.D.
Derks, S.
Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
title Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
title_full Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
title_fullStr Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
title_full_unstemmed Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
title_short Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
title_sort pre-treatment tumor-infiltrating t cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344794/
https://www.ncbi.nlm.nih.gov/pubmed/34377591
http://dx.doi.org/10.1080/2162402X.2021.1954807
work_keys_str_mv AT goedegebuurersa pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT harrasserm pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT deklerklk pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT vanschootents pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT vangriekennct pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT ekenm pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT grifhorstms pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT pocornin pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT jordanovaes pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT vanbergehenegouwenmi pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT pouwre pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT verheulhmw pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT vandervlietjj pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT vanlaarhovenhwm pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT thijssenvljl pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT bassaj pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT degruijltd pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma
AT derkss pretreatmenttumorinfiltratingtcellsinfluenceresponsetoneoadjuvantchemoradiotherapyinesophagealadenocarcinoma